Table 1.
Clinical characteristics of CD5+ and CD5− non-DE DLBCL patients. .
| Characteristic | CD5+ (n = 48) | 2.1.1.1 CD5− (n = 481) | p |
|---|---|---|---|
| Median age, years (range) | 57 (25–90) | 58 (16–90) | |
| Gender | 0.079 | ||
| Men Women |
32 (66.7%) 16 (33.3%) |
257 (53.4%) 224 (46.6%) |
|
| Ann Arbor, n (%) | 0.021 | ||
| I–II | 21 (43.7%) | 293 (60.9%) | |
| III–IV | 27 (56.3%) | 188 (39.1%) | |
| LDH, n (%) | 0.241 | ||
| > Normal | 26 (54.2%) | 218 (45.3%) | |
| ≤ Normal | 22 (45.8%) | 263 (54.7%) | |
| ECOG, n (%) | 0.330 | ||
| < 2 | 43 (89.6%) | 449 (93.3%) | |
| ≧ 2 | 5 (10.4%) | 32 (6.7%) | |
| IPI, n (%) | 0.010 | ||
| 0–2 | 27 (56.2%) | 355 (73.8%) | |
| 3–5 | 21 (43.8%) | 126 (26.2%) | |
| Age > 60 years, n (%) | 19 (39.6%) | 202 (42%) | 0.747 |
| Extranodal sites, n (%) | 0.231 | ||
| ≧ 2 | 15 (31.3%) | 113 (23.5%) | |
| < 2 | 33 (68.7%) | 368 (76.5%) | |
| Cell of origin | 0.443 | ||
| Non-GCB | 30 (62.5%) | 373 (56.8%) | |
| GCB | 18 (37.5%) | 208 (43.2%) | |
| Response | 0.413 | ||
| CR | 38 (79.2%) | 403 (83.8%) | |
| Non-CR | 10 (20.8%) | 78 (16.2%) | |
| Bone marrow involvement, n (%) | 8 (16.7%) | 31 (6.4%) | 0.018 |
| CNS relapse, n (%) | 3 (6.3%) | 6 (1.3%) | 0.040 |
DLBCL, diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; IPI, international prognostic index; GCB, germinal center B-cell; CR, complete remission; CNS, central nervous system.